Cambridge Healthtech Institute's 11th Annual

WPC World Pharma Congress

June 5 - 7, 2012

Loews Philadelphia Hotel, Philadelphia, PA

Register by May 4
SAVE up to $200!

Promising Assays and Technologies for Better Pre-Clinical Predictions

June 5 - 6

Predicting Drug-Induced Cardiotoxicity

Targeting Alzheimer's Disease

Predictive Pre-Clinical Models in Oncology

June 6 - 7

Tackling Drug-Induced Idiosyncratic Hepatotoxicity

Molecular Imaging in Drug Discovery and Development

Targeting Pain with Novel Therapeutics

WPC Short Courses & Symposia

Short Courses

- Addressing Safety Concerns for Biological Drugs
- Animal Models of Pain: Progress and Challenges
- Mechanistic Insights into Cardiotoxicity
- Mechanistic Insights into Hepatotoxicity
- Use of Stem Cells for Safety Screening
- Molecular Imaging in Drug Discovery and Development: Back to Basics
- Patient Derived Cancer Tissue Xenograft Models
- Recent Developments in Ion Channel Assays for Safety Screening
- Translating Biomarkers from the Lab to the Clinic

Pre-Conference Symposium

- Targeting Parkinson's Disease

Organized by Cambridge Healthtech Institute

WorldPharmaCongress.com

Corporate Sponsors

ALGOS PRECLINICAL SERVICES
CHAMPIONS ONCOLOGY
ChanTest THE ION CHANNEL EXPERT
The Jackson Laboratory
maccine
MSD Meso Scale Discovery
METABOLON
Molecular Imaging
MOLECULAR RESPONSE
PsychoGenics
QUINTILES
Roche
SIGMA Life Science
Strand
VIVO BIOSCIENCES ADVANCING DRUG DEVELOPMENT
XenoBiotic Laboratories, Inc.

WPC Conference-at-a-Glance

Monday June 4	**Pre-Conference Short Courses and Symposia***		
	SYMPOSIUM: Targeting Parkinson's Disease		
Tuesday June 5	Predicting Drug-Induced Cardiotoxicity	Targeting Alzheimer's Disease	Predictive Pre-Clinical Models in Oncology
Wednesday June 6	Predicting Drug-Induced Cardiotoxicity	Targeting Alzheimer's Disease	Predictive Pre-Clinical Models in Oncology
	Tackling Drug-Induced Idiosyncratic Hepatotoxicity	Targeting Pain with Novel Therapeutics	Molecular Imaging in Drug Discovery and Development
	Dinner Short Courses*		
Thursday June 7	Tackling Drug-Induced Idiosyncratic Hepatotoxicity	Targeting Pain with Novel Therapeutics	Molecular Imaging in Drug Discovery and Development

Separate registration required

There is much to look forward to at the World Pharma Congress 2012 and here are some reasons why you don't want to miss being there!

- It's one of the few conferences that focuses heavily on pre-clinical efforts targeted towards early discovery, screening and safety assessments
- It brings together the right mix of scientists and clinicians to facilitate active brainstorming and networking on key issues
- It draws together experts from industry and academia, working on tackling some of the most challenging issues in the field
- Pre-conference workshops offer an opportunity for people to interact with experts in an interactive and informal setting
- It includes contributions from leading technology and service providers on the latest tools and services available in the marketplace
- Informative roundtables, panel discussions, poster sessions and other networking opportunities provide a stimulating environment for communication and collaboration

So whether you are a seasoned attendee or joining us for the first time, we look forward to welcoming you in Philadelphia!

Maximize your experience on-site at World Pharma Congress 2012!

CHI's INTRO-NET Networking at its Best

The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people you want to meet. This online system was designed with your privacy in mind and is available only to registered session attendees of this event. Registered conference attendees will receive more information on accessing the Intro-Net in the weeks leading up to the event!

Present a poster and save $50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by April 20, 2012. Please see registration page for details.

Reasons you should present your research poster at this conference:

- Your poster will be exposed to our international delegation
- Your poster abstract will be published in our conference materials
- Receive $50 off your registration
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes

Co-Located Event **June 4-5**

Innovative Tissue-Based Diagnostics

Decoding Cancer & Other Maladies

For more information and to register, visit: **healthtech.com/TDX**

Save 10% off the current registeration rate. Reference keycode TDX10

Corporate Support Sponsor

ACEA Biosciences, Inc.

Sponsoring Organizations

D-S-E-C

2012 World Molecular Imaging Congress

Lead Sponsoring Publications

Bio-IT World

ddn Drug Discovery News

GEN Genetic Engineering & Biotechnology News

Genome Technology

nature

Science AAAS

The Scientist

Sponsoring Publications

Aging Health

Bentham Science

BioCentury

BioPharm International

Cell Therapy News

Current Pharmaceutical Biotechnology

Current Pharmaceutical Design

Future Neurology

Imaging in Medicine

International Drug Discovery

JAD

JPD Journal of Parkinson's Disease

NeuralCell News

PharmaVOICE

Web Partners

BioSpace.com

genomeweb

labroots.com

www.PharmCast.com – Pharmaceutical Internet –

SelectScience.net

Media Partners

Bio-Outsourcing Asia

IOS Press

MarketsandMarkets

ReportsandReports

WPC Sponsorship & Exhibit Information

The World Pharmaceutical Congress presents your company with the opportunity to network with decision-makers and leading professionals from all aspects of the biopharmaceutical community. Become a sponsor in order to influence, network, and interact with over 500 highly qualified, targeted delegates.

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding, as well as the use of the pre and post show delegate list. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company's needs and budget. Signing on earlier will allow you to maximize exposure to hard-to-reach decision makers!

What are the benefits of a sponsored presentation?

- Presentations take place in the main session room as part of the main agenda, ensuring a high ROI for your company, as attendees are a guaranteed audience.
- Your presentation will be promoted throughout all conference materials as part of the main conference program!

Sponsored Presentations

Showcase your solutions to a guaranteed, highly-targeted audience. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding and access to cooperative marketing efforts by CHI.

Breakfast & Luncheon Presentations

Opportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite

Sponsors will hand-pick their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor's objectives (i.e. purely social, focus group, reception style or plated dinner, plated dinner with specific conversation focus.

User Group Meetings

Co-locate your user group meeting with World Pharma Congress 2012. CHI will help market the event, manage logistical operations, develop the agenda, and more.

CHI Lead Generation:

CHI can help you with lead generation throughout the year. Our internal database includes over 800,000 prospects in the life sciences. By leveraging the database and mining for your specific requirements, we can produce multiple custom projects which will deliver your prospective buyers: Web Symposiums, Podcasts, White Papers, Custom Market Research Surveys and more!

Exhibit Information

Exhibitors will enjoy facilitated networking opportunities with over 500 qualified decision-makers at the World Pharma Congress, making it the perfect platform to launch a new product, collect feedback and generate new leads. Exhibit space sells out quickly, so reserve yours today!

How will CHI ensure that delegates visit the exhibit hall?

CHI is committed to ensuring that all delegates visit the exhibit hall by holding welcoming receptions, refreshment breaks, and raffles!

Additional promotional opportunities include, but are not limited to:

- Sponsorship of Event Short Courses
- Sponsorship of Conference Symposia
- Badge Lanyards Sponsor
- Exhibit Hall Reception
- Hotel Room Door Hanger (1 night exclusive)
- Hotel Room Drop
- Keynote Chair Drop
- Specific Conference Chair Drop
- Padfolio Sponsor
- Refreshment Break
- Tote Bag Sponsor
- Tote Bag Insert
- Program & Exhibit Guide Sponsor

For sponsorship & exhibit information, please contact:

Joseph Vacca
Manager, Business Development
T: 781-972-5431 C: 781-687-9400 E: jvacca@healthtech.com

2011 Sponsors & Exhibitors

Algos Preclinical Services
Aperio Technologies
Bioscan, Inc.
Carestream Molecular Imaging
CCS Cell Culture Service, Inc.
Cellular Dynamics International
ChanTest
CiT
Corning, Inc
Data Sciences International
EMD Millipore
Fluofarma
GlobalStem
Hepregen Corporation
IntelliCyt Corporation
InterMed Discovery, GmbH
inviCRO
The Jackson Laboratory
KineMed Inc.
Meso Scale Discovery
Molecular Imaging Research, Inc.
Nexcelom Bioscience
Promega
PsychoGenics Inc.
Ricerca Biosciences
Roche Diagnostics Corporation
Rules Based Medicine
SAS Institute (JMP Life Sciences)
Scottish Biomedical
Sigma Life Sciences
Tecan
Venenum Biodesign
Zalicus, Inc.

Hotel & Travel Information

Conference Hotel

Loews Philadelphia Hotel
1200 Market Street
Philadelphia, PA 19107
Phone: 215-627-1200 **Reservations: worldpharmacongress.com**

Discounted Room Rate: $209 s/d
Discounted Cut-off Date: May 8, 2012

Please visit our website to make your reservations online or you may also call the hotel directly to reserve your sleeping accommodations.

You will need to identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate with the host hotel. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space- and rate-availability basis. Rooms are limited, so please book early.

Flight Discounts

Special discount rates have been established with American Airlines for this conference.

- Call 1-800-433-1790 and use Conference code 7162AX.
- Go to www.aa.com/group and enter Conference code 7162AX in promotion discount box.
- Contact our designated travel agents at 1-877-559-5549 or chi@protravelinc.com.

Car Rental Discounts

Special discount rentals have been established with Hertz for this conference.

- Go to www.hertz.com to make your reservation and use our Hertz Convention Number (CV) 04KL0003.
- Or Call Hertz directly at 800-654-3131 and reference our Hertz Convention Number (CV) 04KL0003.

Conference Short Courses*

MONDAY JUNE 4

9-12 pm Addressing Safety Concerns for Biological Drugs

- Overview of challenges pertaining to the safety of biologics
- Tools, markers and assays for early safety predictions
- Assessing immunogenicity and off-target effects
- Regulatory guidelines and their interpretations
- Criteria for determining what needs to be tested and when

Course Instructors:

Eileen R Blasi, M.S., Senior Principal Research Scientist-Pharmacology, Global Safety Pharmacology, Pfizer Global Research & Development

Lisa M. Plitnick, Ph.D., Sr. Investigator, Safety Assessment, Merck & Co., Inc.

9-12 pm Recent Developments in Ion Channel Assays for Safety Screening

- Overview of current and emerging assays and methodologies
- Use of automation and high-throughput techniques
- Comparison of platforms and applications
- Factors affecting sensitivity and specificity
- Correlation between in vitro and in vivo testing

Course Instructors:

Gul Erdemli, M.D., Ph.D., DABT, Head of Ion Channel Group, Novartis Institutes for BioMedical Research, Inc.

Glenn Kirsch, Ph.D., Senior Director, Pharmacology and Program Management, ChanTest Corporation

2-5 pm Use of Stem Cells for Safety Screening

- Differentiation of human stem cells into cardiac myocytes and hepatocytes
- Comparison of electrophysiology and pharmacology
- Overcoming technical challenges related to working with stem cells
- Methodologies to maintain and use stem cells for predictive safety testing

Course Instructors:

Andrew Bruening-Wright, Ph.D., Study Director, ChanTest Corporation

Craig T. January, M.D., Ph.D., Professor, Medicine and Physiology, Division of Cardiovascular Medicine, University of Wisconsin-Madison

Emile Nuwaysir, Ph.D., Vice President and COO, Cellular Dynamics International

2-5 pm Mechanistic Insights Into Cardiotoxicity

- Genetics, physiology and risks in human heart failure
- Mechanisms underlying sex differences in ion channel expression and their role in arrhythmia phenotype
- Sex differences in the severity of ischemic injuries and in general, the effects of sex steroids in metabolic injuries

Course Instructors:

Barry London, M.D., Ph.D., Director, Cardiovascular Institute; Chief , Division of Cardiology; Professor of Medicine, Cell Biology & Physiology, University of Pittsburgh School of Medicine

Cynthia Carnes, Pharm.D., Ph.D., Associate Dean for Graduate Studies and Research, and Professor, Pharmacy Practice and Administration, Ohio State University

Guy Salama, Ph.D., Professor, Department of Medicine, University of Pittsburgh School of Medicine

Xander Wehrens, M.D., Ph.D., Chair and Professor, Department of Medicine, Division of Cardiology, Baylor School of Medicine

2-5 pm Translating Biomarkers from the Lab to the Clinic

- Design and implementation of studies to identify new biomarkers
- Designing clinical studies to test and validate biomarker
- Clinical methodologies for cost-effective and reliable decision-making
- Bridging the gap between pre-clinical and clinical findings
- Practical considerations when using biomarkers in the clinic

6-9 pm DINNER SHORT COURSE: Patient Derived Cancer Tissue Xenograft Models

Sponsored by The Jackson Laboratory

- Cutting edge xenografting methods
- Value and the limitations of xenograft models
- Case studies of preclinical trials using patient derived xenograft models

Neal Goodwin, Ph.D., Director, Research and Development, In Vivo Pharmacology Services, The Jackson Laboratory

Melinda Hollingshead, D.V.M., Ph.D., Chief, Biological Testing Branch, NCI-FCRDC Fairview Center

Regina Gandour-Edwards, M.D., Director, Cancer Center Biorepository, Professor, Vice Chair Education, Department of Pathology and Laboratory Medicine, UC Davis

WEDNESDAY JUNE 6

9-12 pm Animal Models of Pain: Progress and Challenges

- Implementation of classical models of acute, tonic and chronic pain
- Limitations of these classical models
- Refinement of classical models via a consideration of modulatory factors (sex, genetics, testing environment, social modulation)
- Development of new animal models (e.g., operant methods, spontaneous behaviors)

Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies, McGill University

6-9 pm DINNER SHORT COURSE: Molecular Imaging in Drug Discovery and Development: Back to Basics

2012 World Molecular Imaging Congress

- Strength and limitations of various imaging modalities
- Multimodality imaging
- Generation of imaging agents for optical, MR, and nuclear imaging
- Image analysis

Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.

6-9 pm DINNER SHORT COURSE: Mechanistic Insights Into Hepatotoxicity

- Mitochondrial dysfunction and oxidative stress
- Inflammation
- Excessive generation of reactive metabolites
- Inhibition of bile salt efflux protein and involvement of hepatic transporters in drug-induced hepatotoxicity

Course Instructors:

José E. Manautou, Ph.D., Associate Professor of Toxicology, Department of Pharmaceutical Sciences, University of Connecticut

Robert A. Roth, Ph.D., DABT, Professor of Pharmacology and Toxicology, Director, Graduate Program in Environmental and Integrative Toxicological Sciences, Michigan State University

Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

**Separate Registration Required*

Targeting Parkinson's Disease

Novel Approaches to Disease Modification and Symptom Suppression

MONDAY, JUNE 4

8:00-9:00 am Morning Coffee, Pre-Conference Short Course & Symposia Registration

Program Scientific Advisor: Susan E. Browne, Ph.D., Director, Neuropharmacology, Merck Research Labs

NOVEL TARGETS

9:00 Chairperson's Remarks

Susan E. Browne, Ph.D., Director, Neuropharmacology, Merck Research Labs

9:05 The Discovery and Development of Positive Allosteric Modulators of mGlu4 for the Treatment of Parkinson's Disease

Corey R. Hopkins, Ph.D., Research Assistant Professor, Associate Director, Medicinal Chemistry, Drug Discovery Program, Vanderbilt

9:35 Sirt1 Protects Against a-Synuclein Aggregation by Activating Molecular Chaperones

Gizem Donmez, Ph.D., Assistant Professor, Neuroscience, Tufts University School of Medicine

10:05 Glucocerebrosidase Associated Synucleinopathies: Potential Mechanisms

Grisel Lopez, M.D., Senior Staff Clinician, National Human Genome Research Institute, Section on Molecular Neurogenetics, Medical Genetics Branch, NIH

10:30 Coffee Break

LRRK2

11:00 Novel Tools for LRRK2 Research

Sonal S. Das, Ph.D., Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research

11:30 Targeting LRRK2 for Parkinson's Disease Pathogenesis and Therapeutics

Wanli W. Smith, M.D., Ph.D., Assistant Professor, Head, Molecular Neuroscience Laboratory, Pharmaceutical Sciences, University of Maryland School of Pharmacy

12:00 The Challenges of LRRK2 as a Therapeutic Target

Warren Hirst, Ph.D., Associate Research Fellow, Neurodegeneration, Pfizer

12:30 pm Enjoy Lunch on Your Own

LIDS DRUG DISCOVERY & DEVELOPMENT

1:45 Chairperson's Remarks

Kuldip Dave, Ph.D., Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research

1:50 Exploring the Potential of Modified Release Aminoadamantanes in Parkinson's Disease and Related Indications

Gregory Went, Ph.D., CEO & Chairman, Adamas Pharmaceuticals

2:20 Progress on Allosteric Modulation of mGluR5 and mGluR4: Towards New Treatment Paradigms in Parkinson's Disease

Sonia-Maria Poli, Ph.D., Head, NCD and CNS programs, NCD, Addex Pharmaceuticals

2:50 Targeting G Protein-Coupled Receptor Kinases to Combat Runaway Dopamine Receptor Signaling in L-DOPA-Induced Dyskinesia

Eugenia Gurevich, Ph.D., Associate Professor, Pharmacology, Vanderbilt University

3:20 Refreshment Break

DRUG REPOSITIONING – PRE-CLINICAL

» 3:45 KEYNOTE ADDRESS: REPOSITIONING DRUGS FOR PARKINSON'S DISEASE

Kuldip Dave, Ph.D., Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research

4:15 End of Day

TUESDAY, JUNE 5

7:15 am Morning Coffee

BIOMARKERS FOR NEURODEGENERATIVE DISCOVERY

8:00 Chairperson's Opening Remarks

Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals

8:10 Talk Title to be Announced

Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals

8:40 Hunting for IgG Biomarkers for Alzheimer's

Dwight German, Ph.D., Professor, Department of Psychiatry, University of Texas Southwestern Medical Center

9:10 Sponsored Presentations (Opportunities Available)

9:40 Surgery and Anesthesia as Modifiers of Alzheimer's Trajectory

Roderic G. Eckenhoff, M.D., Vice Chair for Research, Austin Lamont Professor of Anesthesiology & Critical Care, Perelman School of Medicine, University of Pennsylvania

10:10 End of Symposium

**Separate Registration Required*

TUESDAY, JUNE 5

7:15 am Registration & Morning Coffee

EARLY ASSESSMENTS: ASSAYS, MODELS AND MARKERS

8:30 Chairperson's Opening Remarks
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories

8:40 Cellular QT Screens - Probing Adult Cardiac Myocytes
Lars Kaestner, Ph.D., Principal Investigator, Institute for Molecular Cell Biology, Saarland University

9:10 Evaluation of Cellular Impedance Measures of Cardiomyocyte Cultures for Drug Screening Applications
Matthew Peters, Ph.D., Principal Scientist, Safety Assessment, Astrazeneca

9:40 The Tell Tale Heart: Integration of Whole Heart Energetics, Proteomics, and Function to Assess Cardiac Toxicity in the Isolated Heart
Brian Roche, Ph.D., Cardiovascular Safety Pharmacologist, Safety Pharmacology, Battelle Memorial Institute

10:10 Coffee Break

10:40 Cardiac Contractility: Challenges in De-Risking
Jonathan Heyen, Ph.D., Principal Scientist, Global Safety Pharmacology, Pfizer Global Research & Development

11:10 Translating Cardiotoxicity: Can Stem Cells "Swim" Like Humans?
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories

11:40 Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Understand Mechanisms of Cardiotoxicity
Dinesh Puppala, Ph.D., Senior Scientist, Compound Safety Prediction Group, Pfizer, Inc.

12:10 Translational Cardiovascular Safety: Optimizing the Integration of Preclinical and Clinical Safety Data
Sponsored by QUINTILES
Sarah S. Bacus, Ph.D., CSO & Senior Vice President, Innovation, Quintiles Pacific, Inc.

12:40 pm Luncheon Presentation
Using Stem Cell-derived Cardiomyocytes in Drug Screening and Predictive Cardiotoxicity
Sponsored by SIGMA Life Science
Silke Schwengberg, Ph.D., Senior Scientist, Research and Development, Axiogenesis AG
Cardiomyocytes derived from pluripotent stem cells are an attractive in vitro model due to standardized large scale production process, stability in long-term culture, and relevant physiology. In combination with advanced assay technologies, cardiac drug efficacy and safety assessment data have become more predictive. Cor.At® cardiomyocytes have been functionally validated for several cardiotoxicity assays including drug-induced cardiac-specific cytotoxicity as well as mitochondrial toxicity of different compound classes including anthracyclines as well as tyrosine kinase inhibitors.

1:10 Session Break

NEW INSIGHTS INTO THE ROLE OF ION CHANNELS

1:30 Chairperson's Remarks
Peter Hoffmann, M.D., Ph.D., Executive Director, Preclinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation

1:40 Cardiac Sodium Channel Inhibition: A Risk Marker During Early Drug Development
Peter Hoffmann, M.D., Ph.D., Executive Director, Pre-Clinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation

2:10 What is New About hERG Channel Inhibition? Atypical hERG Inhibition and Mitigation Strategies

Gul Erdemli, M.D., Ph.D., DABT, Head, Ion Channel Group, Novartis Institutes for BioMedical Research, Inc.

2:40 Regional Genomic Regulation of Cardiac Ion Channels by Estrogen and its Implications to Sex Differences in Arrhythmia Risk
Guy Salama, Ph.D., Professor, Department of Medicine, University of Pittsburgh, School of Medicine

3:10 Channeling Cardiac Risk
Sponsored by ChanTest THE ION CHANNEL EXPERT
Arthur M. "Buzz" Brown, M.D., Ph.D., Executive Chairman & CSO, ChanTest Corporation

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

5:40 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 End of Day

WEDNESDAY, JUNE 6

7:15 am Morning Coffee

EXPLORING CARDIO-ONCOLOGY INITIATIVES

8:00 Chairperson's Remarks
Daniel Lenihan, M.D., Director, Clinical Research, Cardiovascular Medicine, Vanderbilt University

8:10 Early Detection, Prevention and Management of Cardiac Disease During Cancer Therapy
Daniel Lenihan, M.D., Director, Clinical Research, Cardiovascular Medicine, Vanderbilt University

8:40 Surveillance of Patients Undergoing Chemotherapy to Prevent Chemo-Induced Cardiotoxicity
Eugene Storozynsky, M.D., Ph.D., Assistant Professor of Medicine, Program in Heart Failure and Transplantation Division of Cardiology, University of Rochester Medical Center
9:10 Sponsored Presentations (Opportunities Available)

9:40 Coffee Break in the Exhibit Hall with Poster Viewing

10:10 Speaker to be Announced

10:40 Early Cardiovascular De-Risking Strategies for Biotherapeutics and Antibody-Drug Conjugates
Eileen R. Blasi, M.S., Senior Principal Research Scientist, Pharmacology, Global Safety Pharmacology, Pfizer Global Research & Development

11:10 CRO PANEL: Trends in Drug Safety Testing
Moderator: Ernest Bush, Ph.D., Vice President and Research Director, Cambridge Healthtech Associates
Participants:
Glenn Kirsch, Ph.D., Senior Director, Pharmacology and Program Management, ChanTest Corporation
Sarah Bacus, Ph.D., CSO & Senior Vice President, Innovation, Quintiles Pacific, Inc.
Dr. Lisa Minor, President, In Vitro Strategies LLC

12:10 Luncheon Presentations (Sponsorship Opportunities Available) **or Lunch on Your Own**

12:40 pm End of Conference

Tackling Drug-Induced Idiosyncratic Hepatotoxicity

WEDNESDAY, JUNE 6

12:30 pm Registration

TACKLING IDIOSYNCRATIC DILI

1:30 Chairperson's Opening Remarks
Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company

1:40 How to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and Approval?
Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company

» 2:10 KEYNOTE PANEL
Safety in Numbers: Exploring the Pre-Competitive Space
Moderator: Arie Regev, M.D., Eli Lilly and Company
Panelists:
Paul B. Watkins, M.D., Director, Hamner-UNC Institute for Drug Safety Sciences, Verne S. Caviness Distinguished Professor of Medicine, University of North Carolina at Chapel Hill
Richard Miller, D.V.M., Ph.D., DipACVP, Vice President, Safety Assessment, GlaxoSmithKline, Inc.
Stephane Dhalluin, Ph.D., Director, Investigative Non-Clinical Safety, UCB Pharma
Gerry Kenna, Ph.D., Principal Scientist, Hepatic Target Organ Strategy Lead, Safety Assessment, Molecular Toxicology, AstraZeneca

3:10 A Novel *in vitro - in silico* Platform for Predicting Mechanistic Hepatotoxicity
Sponsored by Strand
Sonali Das, Ph.D., Senior Scientist III, Life Science, Strand Life Sciences Pvt Ltd

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:10 Can Biologicals Cause Liver Toxicity?
Paul Vancutsem, D.V.M., Ph.D., Director of Toxicology, Biogen Idec

4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

5:40 End of Day

THURSDAY, JUNE 7

7:30 am Morning Coffee

IN SILICO TOOLS FOR PREDICTING HEPATOTOXICITY

8:00 Chairperson's Remarks
William Salminen, Ph.D., DABT, Director, Center for Hepatotoxicity, National Center for Toxicological Research, Food and Drug Administration

8:10 Computational Approaches for Predicting and Achieving Mechanistic Insight into Zonation Patterns of Hepatotoxicity
C. Anthony Hunt, Ph.D., Department of Bioengineering and Therapeutic Sciences, University of California San Francisco

8:40 Using the DILIsym™ Model to Understand Mechanisms of Hepatotoxicity
Brett A. Howell, Ph.D., Research Investigator, The Hamner - UNC Institute for Drug Safety Sciences

9:10 Virtual Liver: Quantitative *in vitro* to *in vivo* Extrapolation Using Systems Biology
Imran Shah, Ph.D., Head, Computational Systems Biology, National Center for Computational Toxicology, U.S. Environmental Protection Agency

9:40 Sponsored Presentations (Opportunities Available)

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

NEW TOOLS AND MARKERS FOR STUDYING LIVER INJURY

Chairperson: *Eric Blomme, D.V.M., Ph.D., DACVP, Director, Investigative Toxicology and Pathology, Senior Research Fellow, Abbott Laboratories*

10:40 *In vivo* Imaging of the Effects of Drugs on Hepatic Transport Using Quantitative Multi-photon Microscopy
Kenneth Dunn, Ph.D., Associate Professor of Medicine and Biochemistry, Indiana University

11:10 Using microRNA as Biomarkers of Drug-Induced Liver Injury
William Salminen, Ph.D., DABT, Director, Center for Hepatotoxicity, National Center for Toxicological Research, Food and Drug Administration

11:40 Use of Non-Traditional Rodent Models to Characterize and Predict Drug-induced Liver Injury
Eric Blomme, D.V.M., Ph.D., DACVP, Director, Investigative Toxicology and Pathology, Senior Research Fellow, Abbott Laboratories

12:10 Early Assessment of Hepatotoxicity Potential of NCEs Using a Variety of *in vitro* Approaches
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

12:40 pm Luncheon Presentations (Sponsorship Opportunities Available) **or Lunch on Your Own**

1:10 Session Break

INSIGHTS INTO MECHANISMS OF LIVER TOXICITY

1:30 Chairperson's Remarks
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

1:40 Transporter Strategies in Discovery and Development: Drug-Drug Interactions and Safety Implications
Praveen Balimane, Ph.D., Senior Research Investigator, Metabolism and Pharmacokinetics Group, Bristol-Myers Squibb Co.

2:10 Development of Novel, High-Throughput Transporter Assays for Human Drug Transporters
Mary Ellen Cvijic, Ph.D., Principal Scientist, Lead Evaluation, Molecular Sciences and Candidate Optimization, Bristol-Myers Squibb Co.

2:40 Analysis of Changes in Hepatic Gene Expression in a Murine Model of Tolerance to Acetaminophen Hepatotoxicity (Autoprotection)
José E. Manautou, Ph.D., Professor of Toxicology, Department of Pharmaceutical Sciences, University of Connecticut

3:10 Talk Title to be Announced
Patricia Ganey, Ph.D., Professor, Pharmacology and Toxicology, Center for Integrative Toxicology, Michigan State University

3:40 End of Conference

TUESDAY, JUNE 5

7:15 am Registration & Morning Coffee

Program Scientific Advisor: *Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women's Hospital*

BIOMARKERS FOR NEURODEGENERATIVE DISCOVERY

8:30 Chairperson's Opening Remarks

Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals

8:40 Talk Title to be Announced

Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals

9:10 Hunting for IgG Biomarkers for Alzheimer's

Dwight German, Ph.D., Professor, Department of Psychiatry, University of Texas Southwestern Medical Center

9:40 Surgery and Anesthesia as Modifiers of Alzheimer's Trajectory

Roderic G. Eckenhoff, M.D., Vice Chair for Research, Austin Lamont Professor of Anesthesiology & Critical Care, Perelman School of Medicine, University of Pennsylvania

10:10 Coffee Break

10:40 Selected Poster Presentation: An Amyloid Seeding Assay (ASA) for the Early Detection of Protein Misfolding

Sharad Gupta, Ph.D., Post-doctoral Fellow, Biochemical and Chemical Engineering, University of Delaware

NOVEL APPROACHES TO DRUG DISCOVERY THROUGH ALTERNATIVE TARGETS

11:10 Novel NMDA Receptor Antagonists for Treatment of AD

Adeboye Adejare, Ph.D., Professor, Pharmaceutical Sciences, University of the Sciences, Philadelphia College of Pharmacy

11:40 PP2A – A Novel Target for Alzheimer's Disease Therapeutics

Steven Braithwaite, Ph.D., Senior Vice President, Drug Discovery, Neuroscience, Signum Biosciences

12:10 pm Luncheon Presentation

Development of Analytically Validated CSF Biomarker Assays for Alzheimer's Disease

Sponsored by MSD Meso Scale Discovery

Pankaj Oberoi, Ph.D., Director, Scientific Services and Research & Development, Meso Scale Discovery

1:10 Session Break

Chairperson's Remarks

Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women's Hospital

1:25 Enhancing Antibody Uptake in Brain to Target BACE1

Jasvinder K. Atwal, Ph.D., Senior Research Associate, Neuroscience, Genentech

1:55 Translation in Alzheimer's Disease: Value Added through Preclinical *in vivo* Testing in the Primate?

Sponsored by maccine

Jeffrey A. Vivian, Ph.D., Department of Neuroscience, Maccine Pte Ltd

2:10 Moderated Speaker Q&A Panel

Moderator: Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology; Center for Neurologic Diseases Brigham and Women's Hospital

Speakers from the neurodegenerative biomarker and novel target session will address current topics in AD research. Audience participation is encouraged and the moderator will have prepared questions for the panelists.

» 2:40 KEYNOTE PRESENTATION

Converting Knowledge of Ab Biology into Disease-Modifying Therapeutics

Dennis J. Selkoe, M.D., Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School; Co-Director, Center for Neurologic Diseases, Brigham and Women's Hospital

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:40 Interactive Discussion Groups

Animal Models for AD and PD- Should we Skip the Preclinical Models?

Moderator: Susan E. Browne, Ph.D., Director, Neuropharmacology, Merck Research Labs

Animal Models for Neurodegenerative Diseases Drug Discovery

Moderator: Sylvie Ramboz, Ph.D., Vice President, Neurodegenerative Disorders, PsychoGenics

5:40 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 End of Day

WEDNESDAY, JUNE 6

7:15 am Morning Coffee

UPDATES ON PRE-CLINICAL CANDIDATES AND THEIR TARGETS

8:00 Chairperson's Remarks

8:10 New Therapeutic Approach for Alzheimer's Disease: Small-Molecule Structure Correctors Targeting ApoE4

Robert W. Mahley, M.D., Ph.D., President Emeritus, The J. David Gladstone Institutes; Professor, Pathology, Medicine, University of California, San Francisco

8:40 A Novel, Potent, and Selective Modulator of Gamma Secretase

Barbara Tate, Ph.D., Vice President, Biology, Satori Pharmaceuticals

9:10 Small Molecule Gamma-Secretase Inhibitors for the Treatment of Alzheimer's Disease

Han-Xun Wei, Ph.D., Senior Chemist, Laboratory for Experimental Alzheimer's Drugs, Harvard Medical School

9:40 Coffee Break in the Exhibit Hall with Poster Viewing

10:10 Microglia Activation in the Alzheimer Brain; Normalization by Posiphen®

Maria L. Maccecchini, Ph.D., President, CEO, QR Pharma

BETTER DIAGNOSIS, DISCOVERY AND DEVELOPMENT THROUGH IMAGING

10:40 Biomarkers for Alzheimer's – An ADNI Perspective

Neil Buckholtz, Ph.D., Chief, Dementias of Aging Branch, Division of Neuroscience, National Institute on Aging

11:10 Translational Imaging in Alzheimer's Disease Clinical Trials

Stephen Salloway, M.D., M.S., Director, Neurology and the Memory and Aging Program, Butler Hospital; Professor, Clinical Neurosciences and Psychiatry, The Warren Alpert Medical School of Brown University

11:40 Translatable Pre-Clinical Imaging Approaches for Assessing Alzheimer's Disease and Pharmacologic Effects in Animals

Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics, Precision Medicine, Worldwide Research & Development, Pfizer, Inc.

12:10 pm End of Conference

WEDNESDAY, JUNE 6

12:30 pm Registration

1:20 Chairperson's Opening Remarks
Jeffrey Kennedy, Ph.D., Senior Research Fellow, Neuroscience Discovery Research, Eli Lilly & Co.

» 1:25 KEYNOTE PRESENTATION
From Mechanisms to Medicines: What ACTTION Can be Taken to Accelerate Analgesic Drug Development?
Robert H. Dworkin, Ph.D., Professor of Anesthesiology, Neurology, Oncology, and Psychiatry; Professor, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry; Director, Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the FDA

EARLY ASSESSMENT OF CLINICAL EFFICACY

2:10 A Novel Genetic Based Approach for Demonstrating Target Engagement of Nav1.7 Inhibitors
Y. Paul Goldberg, M.B., Ch.B., Ph.D., FRCPC, Vice-President, Clinical Development, Xenon Pharmaceuticals, Inc.

2:40 Pharmacology and First Clinical Experience of the Dual Enkephalinase Inhibitor PL37
Bernard P. Roques, Ph.D., Vice President & Scientific Director, Pharmaleads
Michel Wurm, M.D., Director, Drug and Business Development, Pharmaleads

3:10 Sponsored Presentations (Opportunities Available)

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:10 Talk Title to be Announced
Anthony W. Bannon, Ph.D., Associate Director II, Neuroscience Drug Discovery, Global Pharmaceutical Research & Development, Abbott

4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

5:40 End of Day

THURSDAY, JUNE 7

7:30 am Morning Coffee

RETHINKING ANIMAL MODELS & PREDICTIVITY

8:00 Chairperson's Remarks
Edward Bilsky, Ph.D., Professor, Pharmacology & Director, Center of Excellence in the Neurosciences, University of New England

8:10 Rat Models of Pain-Induced Sleep Disturbance: An Objective Measure of Non-Evoked Discomfort
Steve McGaraughty, Ph.D., Head, Electrophysiology, Abbott Labs

8:40 Development and Validation of a Novel Conflict-Avoidance Paradigm to Assess Acute and Chronic Nociception in Rodents
Steven E. Harte, Ph.D., Chronic Pain and Fatigue Research Center, Departments of Anesthesiology and Internal Medicine/Rheumatology, University of Michigan Medical School

9:10 Talk Title to be Announced
Kelly Knopp, Ph.D., Senior Research Scientist, Neuroscience, Lilly Research Labs

9:40 High Throughput Automated Behavioral Assessment Improves Translation in Analgesic Drug Discovery
Sponsored by PsychoGenics
Emer Leahy, Ph.D., President & CEO, PsychoGenics Inc.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:40 PANEL DISCUSSION: THE EVOLVING ROLE OF THE CRO
Jim Pomonis, Ph.D., Director, Technical Development, Algos Preclinical Services
Garth Whiteside, Ph.D., Director, Discovery, Purdue Pharma
William J. Martin, Ph.D., Senior Director, Pharmacology, Theravance, Inc.
Elizabeth Eberle, Operations Manager, Covance
Kelly Knopp, Ph.D., Senior Research Scientist, Neuroscience, Lilly Research Labs

NEW APPROACHES FOR CHALLENGING TARGETS

11:40 Discovery of Allosteric Small Molecule Inhibitors of the NGF/TrkA Pathway—A New Approach to Treating Inflammatory Pain
Steven Andrews, Ph.D., Associate Director, Drug Discovery, Medicinal Chemistry, Array BioPharma

12:10 GABAB Receptor Positive Allosteric Modulators (PAM) show Superior Tolerability while Demonstrating Analgesic Activity in Pre-Clinical Models of Inflammatory, Visceral and Chronic Osteoarthritis Pain
Sonia Poli, Ph.D., Head, Non-Clinical Development, Addex Pharma

12:40 pm Luncheon Presentations (Sponsorship Opportunities Available) **or Lunch on Your Own**

1:10 Session Break

TARGETING THE ENDOCANNABINOID SYSTEM

1:30 Chairperson's Remarks

1:40 The Endocannabinoid System: New Insights into its Role in the Control of Pain
Daniele Piomelli, Ph.D., Drug Discovery and Development, Italian Institute of Technology; Department Pharmacology, University of California, Irvine

2:10 Integrated Biomarker Approaches in the Discovery and Development of FAAH Inhibitors for Pain
Darrell A. Henze, Ph.D., Biology Program Team Lead, Pain and Migraine Research, Merck Research Laboratories

ADVANCES WITH ION CHANNELS FOR PAIN

2:40 Discovery of Subtype Selective Sodium Channel Modulators
Richard Butt, Ph.D., Director, Research Project Leader, Pain Therapeutics, Pfizer Neusentis

3:10 CNV2197944, a Novel, Potent and Selective Cav2.2 State-Dependent Blocker for Evaluation of Chronic Pain
Valerie Morisset, Ph.D., Head, Electrophysiology, Convergence Pharmaceuticals

3:40 End of Conference

STAY CONNECTED!
Follow us on Twitter @chi_healthtech #WPC12
Join the World Pharma Congress group

TUESDAY, JUNE 5

7:15 am Registration & Morning Coffee

PREDICTIVE BIOMARKER IDENTIFICATION IN PRE-CLINICAL MODELS

8:15 Chairperson's Opening Remarks

» 8:25 KEYNOTE PRESENTATION
Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute

9:10 From Cell Lines to Mouse Models: Building Pre-Clinical Oncology Models to Match Targeted Therapies to Cancer Patient Populations
Nancy K. Pryer, Ph.D., Director, Oncology Pharmacology, Novartis Institutes for Biomedical Research

9:40 A Hedgehog-Dependent Barrier to Drug Delivery in Pancreatic Cancer - Translation from Mice to Patients
Kenneth Olive, M.D., Assistant Professor of Medicine and Pathology, Irving Cancer Research Center, Columbia University

10:10 Coffee Break

Sponsored by MOLECULAR RESPONSE

10:40 Beyond Cell Lines: Building Confidence in Predictive Markers Using *Ex Vivo* Drug Treatment Models with Patient Derived Tumor Specimens
Thomas B. Broudy, Ph.D., CSO, Molecular Response

Sponsored by CHAMPIONS ONCOLOGY

10:55 Find the Right Patients for the Right Drugs: Translatable Predictability for Oncology Drug Development
Elizabeth Bruckheimer, Ph.D., Vice President, Scientific Operations, Champions Oncology, Inc.

11:10 Discovery of Candidate Biomarkers of Anticancer Drug Sensitivity by High-Throughput Cell Line Screening
Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center

11:40 Assessing Therapeutic Responses in Genetically Engineered Mouse Models of Cancer
Mallika Singh, Ph.D., Investigator III, Novartis Vaccines and Diagnostics, Inc.

Sponsored by VIVO BIOSCIENCES

12:10 New 3D Micro-tumor Assay Systems for Preclinical and Predictive Oncology Programs: Replicating Human Tumor Biology *In Vitro*
Raj Singh, Ph.D., President & CEO, VIVO BIOSCIENCES, INC.

Sponsored by METABOLON

12:25 pm Luncheon Presentation
Applications of Global Metabolomics in Drug Discovery
Mike Milburn, Ph.D., CSO, Metabolon, Inc.

1:10 Session Break

NOVEL ANIMAL MODELS

1:30 Chairperson's Remarks

1:40 Future Advances in Oncology Drug Development: Characterization Patient-Derived Explants in Comparison to Standard Human Tumor Cell Line-Derived Xenografts
Dr Ching Ching Leow, Sr. Scientist, Cancer Biology, MedImmune

2:10 Exploring of Non-Germline Genetically Engineered Mouse Cancer Models for Translational Discovery and Pre-Clinical Drug Development
Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Pre-Clinical Research, SAIC-Frederick, Inc.

Sponsored by The Jackson Laboratory

2:40 The JAX Patient Derived Xenograft (PDX) Cancer Consortium: Changing the Course of Clinical Advancement
Neal Goodwin, Ph.D., Director, Research and Development, In Vivo Pharmacology Services, The Jackson Laboratory

3:10 Is the Use of Orthotopic Oncology Models a Necessity or a Luxury?
Cedo Bagi, M.D., Ph.D., Senior Research Fellow, Worldwide Comparative Medicine, Global Science & Technology, Pfizer Global R&D

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

Translation from Mice to Patients
Kenneth Olive, M.D., Assistant Professor of Medicine and Pathology, Irving Cancer Research Center, Columbia

Industry-Academia collaboration in The Area of Cancer Models
Mila McCurrach, Project Manager, NFPC, Neurofibromatosis Pre-Clinical Consortium, Children's Tumor Foundation

Cell Lines: Strengths and Limitations
Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center

Genetically Engineered Mouse Models: Strengths and Limitations
Mallika Singh, Ph.D., Investigator III, Novartis Vaccines and Diagnostics, Inc.

5:40 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 End of Day

WEDNESDAY, JUNE 6

7:15 am Morning Coffee

TESTING DRUGS AND FORMULATIONS

8:00 Chairperson's Remarks

8:10 Predicting Efficacy of an Angiopoietin-2 Targeting Therapeutic
Nancy Levin, Ph.D., Director, Biology, CovX Research, Pfizer WRD

8:40 Proven Pre-Clinical Models to Predict Clinical Outcome: Case Examples and Lessons Learned
Handan He, Ph.D., Director, Pre-Clinical PK/PD, DMPK, Translational Sciences, Novartis

9:10 Sponsored Presentations (Opportunities Available)

9:40 Coffee Break in the Exhibit Hall with Poster Viewing

10:10 Development and Application of an Alveolar Soft Part Sarcoma (ASPS) Model
Melinda Hollingshead , D.V.M., Ph.D., Chief, Biological Testing Branch, NCI-FCRDC Fairview

10:40 Developing Polypharmacology Drug Leads with Multigenic Drosophila Models

Ross Cagan, Ph.D., Professor, Developmental & Regenerative Biology, Mount Sinai School of Medicine

INDUSTRY-ACADEMIA COLLABORATION

11:10 The NCI Supported Pediatric Pre-Clinical Testing Program (PPTP)

Peter Houghton, Ph.D., Director, Center for Childhood Cancer, Nationwide Children's Hospital

11:40 The Neurofibromatosis Pre-Clinical Consortium (NFPC): A1Novel Academic-Industry Partnership to Accelerate the Development of Effective New Treatments for NF

Mila McCurrach, Project Manager, NFPC, Neurofibromatosis Pre-Clinical Consortium, Children's Tumor Foundation

12:10 Panel Discussion: Translational Oncology Starts from Predictive Pre-Clinical Models

12: 40 End of Conference

Molecular Imaging in Drug Discovery and Development

WEDNESDAY, JUNE 6

12:30 pm Registration

TECHNOLOGY MATTERS AND BEYOND

1:00 Chairperson's Opening Remarks
Patrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc.

1:10 Industrialized Imaging in a Pharmaceutical Environment
Dinko Gonzalez Trotter, Ph.D., Director, Image Analysis and Physiology, Merck

1:40 Pre-Clinical/Clinical Development and Use of Novel PET Tracers for Establishing Target Expression or Target Binding
Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.

2:10 Image Analysis Approaches to Quantifying MRI and PET Imaging Data
Matt Silva, Ph.D., Director, Research Imaging Sciences, Amgen

2:40 Cerenkov Luminescence Imaging (CLI) and its Utility in the Drug Discovery Process
Robbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company

3:10 Drug Evaluation through Imaging Biomarkers: A CRO Perspective
Patrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc

Sponsored by
Molecular Imaging™
Your science. Our focus.™

3:25 Advanced Techniques in Quantitative Whole Body Autoradiography and Cryo-imaging
Stefan Linehan, Manager, Preclinical Services, XenoBiotic Laboratories, Inc.

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:10 Imaging in Translational Medicine: The BI Approach
Heiko Niessen, Ph.D., Translational Medicine Expert for Clinical Imaging, Translational Medicine, Boehringer Ingelheim Pharma GmbH & CO. KG

4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

Image Analysis: Problems and Solutions
Matt Silva, Ph.D., Director, Research Imaging Sciences, Amgen

fMRI for Drug Discovery: Potentials and Pitfalls
Fuqiang Zhao Ph.D., Senior Research Scientist, Imaging, Merck Research Labs

Imaging for Drug Toxicity Screening
Guillaume Normand, Investigator II, Novartis Pharmaceuticals Corporation

Cerenkov Luminescence Imaging: Strengths and Limitations
Robbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company

5:40 End of Day

6-9 pm DINNER SHORT COURSE:
Molecular Imaging in Drug Discovery and Development: Back to Basics *

2012 World Molecular Imaging Congress

- Strength and limitations of various imaging modalities
- Multimodality imaging
- Generation of imaging agents for optical, MR, and nuclear imaging
- Image analysis

Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.

** Separate Registration Required.*

THURSDAY, JUNE 7

7:30 am Morning Coffee

BIOLOGICS DEVELOPMENT

8:00 Chairperson's Remarks

8:10 Oncologic Applications in Antibody Biodistribution
Simon Williams, Ph.D., Senior Scientist, Biomedical Imaging, Genentech

8:40 Characterization and Pre-Clinical Application of a Therapeutic Monoclonal Antibody-Based PET Tracer
Charlie Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen

9:10 Molecular Imaging as a Tool for Understanding Nervous System Delivery of Biologic Drugs
Ajay Verma, Vice President, Neurodegeneration and Translational Neurology, Biogen Idec

9:40 Sponsored Presentations (Opportunities Available)

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

DRUG TOXICITY SCREENING

10:40 Investigating Cardiotoxicity by Integrative *in vivo* Imaging
Guillaume Normand, Investigator II, Novartis Pharmaceuticals Corporation

11:10 X-Ray Computed Tomography Imaging in Developmental and Reproductive Toxicity Studies
Christopher T. Winkelmann, D.V.M., Ph.D., CT Imaging Lead, Imaging, Merck Research Laboratories

11:40 The Identification of *in vivo* Pre-Clinical Biomarkers for Metabolism-Mediated Toxicity utilizing Near-IR Dyes for *in vivo* Imaging and Proteomic Analysis
Brooke VandenBrink, Scientist, Pharmacokinetics & Drug Metabolism, Amgen

12:10 pm Luciferase-Based Bioimaging to Study Tissue-Specific mdr1 Gene Expression
Susan Kane, Ph.D., Professor, Tumor Cell Biology, City of Hope

12:40 Luncheon Presentations (Sponsorship Opportunities Available) **or Lunch on Your Own**

1:10 Session Break

THERAPEUTIC AREA - SPECIFIC APPLICATIONS

1:30 Chairperson's Remarks

1:40 CARDIOVASCULAR: Imaging Action Potentials - Small Molecule Dyes versus Genetically Encoded Sensors
Lars Kaestner, Ph.D., Principal Investigator, Research Center for Molecular Imaging and Screening, Saarland University

2:10 CANCER: Molecular Imaging of Drug Transporters at the Blood-Brain Barrier
Maria Vlaming, Ph.D., Research Scientist, Pharmacokinetics and Human Studies, TNO, Netherlands Organization for Applied Scientific Research

2:40 PAIN: Pain fMRI in Rat Spinal Cord and Brain: a Tool for Evaluating Efficacy and Mechanism of Action of Analgesics
Fuqiang Zhao Ph.D., Senior Research Scientist, Imaging, Merck Research Labs

3:10 PULMONARY DISEASE: High Resolution Micro-CT as a Powerful Tool to Assess Lung Structural Changes in Preclinical Models of Emphysema and Pulmonary Fibrosis and as a Predictor of Functional Outcomes.
Lawrence de Garavilla, M.S., Ph.D., Research Fellow, Head, Imaging and PK/PD, Immunology Therapeutic Area, Janssen Pharmaceutical

3:40 End of Conference

WPC World Pharma Congress

June 5 - 7, 2012 Loews Philadelphia Hotel, Philadelphia, PA

Pricing and Registration Information

SYMPOSIA AND SHORT COURSE PRICING

Symposium	Commercial	Academic, Government, Hospital-affiliated
Targeting Parkinson's Disease	$1190	$695
Short Course Only		
Single Short Course	$695	$395
Two Short Courses	$1190	$695
Three Short Courses	$1295	$795
Simulcast Live broadcast (remote attendees only) Molecular Imaging in Drug Discovery and Development: Back to Basics Live Broadcast Short Course	$595	$295

Addressing Safety Concerns for Biological Drugs	Molecular Imaging in Drug Discovery and Development: Back to Basics
Animal Models of Pain	Recent Developments in Ion Channel Assays for Safety Screening
Mechanistic Insights into Cardiotoxicity	Translating Biomarkers from the Lab to the Clinic
Patient Derived Cancer Tissue Xenograft Models	Use of Stem Cells for Safety Screening
Mechanistic Insights into Hepatotoxicity	

CONFERENCE PRICING

Standard Package - Multiple Conference Pricing (Includes access to 2 conferences, excludes short courses)	Commercial	Academic, Government, Hospital-affiliated
Advance Registration Until May 4, 2012	$2595	$1075
After May 4, 2012 and On-Site	$2775	$1145

Basic Package - Single Conference Pricing (Includes access to 1 conference, excludes short courses)		
Advance Registration Until May 4, 2012	$1595	$775
After May 4, 2012 and On-Site	$1795	$875

Program Selection ***When registering please indicate the program(s) you will attend:***

June 5th - June 6th	June 6th - June 7th
Predicting Drug-Induced Cardiotoxicity	Tackling Drug-Induced and Idiosyncratic Hepatotoxicity
Targeting Alzheimer's Disease	Targeting Pain with Novel Therapeutics
Predictive Pre-Clinical Models in Oncology	Molecular Imaging in Drug Discovery and Development

Please refer to the Registration Code below:

ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

To view our Substitutions/Cancellations Policy, go to http://www.healthtech.com/regdetails

Video and or audio recording of any kind is prohibited onsite at all CHI events.

If you are unable to attend but would like to purchase the **World Pharma Congress CD** for $750 (plus shipping), please visit worldpharmacongress.com. Massachusetts delivery will include sales tax.

CONFERENCE DISCOUNTS

Poster Submission-Discount ($50 Off)
Poster abstracts are due by April 20, 2012. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. * CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

REGISTER 3 - 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

15% Discount for SAPA Members

25% Discount for Drug Safety Executive Council (DSEC) Members

Alumni Discount SAVE 20%: We appreciate your past participation at World Pharma Congress. Through loyalty like yours, this event has become a must-attend for senior level decision makers. As a result of your great loyalty, we are pleased to extend this exclusive opportunity to save an additional 20% off the registration rate. Simply select the "Alumni Discount" option on the online registration form to take advantage of this special offer. Please note: In order to qualify, our records must indicate you are a past attendee of the World Pharma Congress event. Discounts not applicable on Short Courses (Conference registrations only.)

How to Register: **WorldPharmaCongress.com**

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode **WPC F** when registering!